Technical Analysis for LABP - Landos Biopharma, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Up |
| Historical LABP trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | -2.36% | |
| Calm After Storm | Range Contraction | -2.36% | |
| Fell Below 20 DMA | Bearish | -1.10% | |
| Calm After Storm | Range Contraction | -1.10% | |
| Down 3 Days in a Row | Weakness | -1.10% | |
| 20 DMA Support | Bullish | -1.91% | |
| MACD Bullish Signal Line Cross | Bullish | -1.91% | |
| Calm After Storm | Range Contraction | -1.91% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -2.88% | |
| 20 DMA Support | Bullish | -2.88% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 20 DMA Resistance | 5 minutes ago |
| Gapped Down (Partial) | 5 minutes ago |
| Down 3% | 19 minutes ago |
| Down 2 % | 19 minutes ago |
| Down 1% | 19 minutes ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/13/2021
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate in development is BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and inflammatory bowel diseases. The company also develops NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1, a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and PX-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and rheumatoid arthritis. The company was founded in 2017 and is headquartered in Blacksburg, Virginia.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Autoimmune Diseases Rheumatoid Arthritis Inflammatory Bowel Disease Gastroenterology Colitis Ulcerative Colitis Abdominal Pain Diarrhea Crohn's Disease Diabetic Nephropathy Inflammatory Bowel Diseases
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Autoimmune Diseases Rheumatoid Arthritis Inflammatory Bowel Disease Gastroenterology Colitis Ulcerative Colitis Abdominal Pain Diarrhea Crohn's Disease Diabetic Nephropathy Inflammatory Bowel Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 16.989 |
| 52 Week Low | 8.84 |
| Average Volume | 46,285 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 11.32 |
| 20-Day Moving Average | 10.94 |
| 10-Day Moving Average | 10.55 |
| Average True Range | 0.64 |
| ADX | 14.16 |
| +DI | 19.76 |
| -DI | 22.22 |
| Chandelier Exit (Long, 3 ATRs) | 10.31 |
| Chandelier Exit (Short, 3 ATRs) | 11.42 |
| Upper Bollinger Bands | 12.14 |
| Lower Bollinger Band | 9.75 |
| Percent B (%b) | 0.54 |
| BandWidth | 21.86 |
| MACD Line | -0.17 |
| MACD Signal Line | -0.23 |
| MACD Histogram | 0.0622 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 11.90 | ||||
| Resistance 3 (R3) | 11.82 | 11.46 | 11.76 | ||
| Resistance 2 (R2) | 11.46 | 11.24 | 11.50 | 11.71 | |
| Resistance 1 (R1) | 11.25 | 11.10 | 11.35 | 11.33 | 11.66 |
| Pivot Point | 10.88 | 10.88 | 10.93 | 10.92 | 10.88 |
| Support 1 (S1) | 10.67 | 10.66 | 10.78 | 10.75 | 10.42 |
| Support 2 (S2) | 10.31 | 10.53 | 10.35 | 10.37 | |
| Support 3 (S3) | 10.10 | 10.31 | 10.32 | ||
| Support 4 (S4) | 10.18 |
